120 related articles for article (PubMed ID: 10478643)
1. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Gratama JW; Zea AH; Bolhuis RL; Ochoa AC
Cancer Immunol Immunother; 1999 Aug; 48(5):263-9. PubMed ID: 10478643
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.
Riccobon A; Gunelli R; Ridolfi R; De Paola F; Flamini E; Fiori M; Saltutti C; Petrini M; Fiammenghi L; Stefanelli M; Granato AM; Cuzzocrea DE; Amadori D
Cancer Invest; 2004; 22(6):871-7. PubMed ID: 15641485
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
4. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.
Franco JL; Ghosh P; Wiltrout RH; Carter CR; Zea AH; Momozaki N; Ochoa AC; Longo DL; Sayers TJ; Komschlies KL
Cancer Res; 1995 Sep; 55(17):3840-6. PubMed ID: 7641202
[TBL] [Abstract][Full Text] [Related]
5. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
6. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Rabinowich H; Banks M; Reichert TE; Logan TF; Kirkwood JM; Whiteside TL
Clin Cancer Res; 1996 Aug; 2(8):1263-74. PubMed ID: 9816296
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
8. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma.
Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A
Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
10. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.
Whiteside TL
Adv Exp Med Biol; 1998; 451():167-71. PubMed ID: 10026868
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
12. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Finke JH; Zea AH; Stanley J; Longo DL; Mizoguchi H; Tubbs RR; Wiltrout RH; O'Shea JJ; Kudoh S; Klein E
Cancer Res; 1993 Dec; 53(23):5613-6. PubMed ID: 8242613
[TBL] [Abstract][Full Text] [Related]
13. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
14. Alteration of signal-transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients.
Kim CW; Choi SH; Chung EJ; Lee MJ; Byun EK; Ryu MH; Bang YJ
Pathobiology; 1999; 67(3):123-8. PubMed ID: 10394132
[TBL] [Abstract][Full Text] [Related]
15. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.
Wersäll P; Mellstedt H
Med Oncol; 1995 Jun; 12(2):69-77. PubMed ID: 8535664
[TBL] [Abstract][Full Text] [Related]
16. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
18. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
[TBL] [Abstract][Full Text] [Related]
19. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function.
Tartour E; Latour S; Mathiot C; Thiounn N; Mosseri V; Joyeux I; D'Enghien CD; Lee R; Debre B; Fridman WH
Int J Cancer; 1995 Oct; 63(2):205-12. PubMed ID: 7591205
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]